Regulations.gov document
Tab 4 - 21 CFR Section 320.24 - "Types of Evidence to Measure Bioavailability or Establish…
Supporting & Related Material · FDA-2007-P-0010 · posted Jun 21, 2009
Key facts
| Document ID | FDA-2007-P-0010-0019 |
|---|---|
| Title | Tab 4 - 21 CFR Section 320.24 - "Types of Evidence to Measure Bioavailability or Establish Bioquivalence" - [Axcan Pharma US, Inc. - Supplement Citizen Petition] |
| Document type | Supporting & Related Material |
| Subtype | SUP-Supplement (Supporting and Related Material) |
| Agency | FDA |
| Docket | FDA-2007-P-0010 |
| Posted | Jun 21, 2009 |
| Effective date | Jun 16, 2009 |
At a glance
- None Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: